Lördag 7 Juni | 11:26:04 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 08:30 Bokslutskommuniké 2025
2025-10-31 10:00 Kvartalsrapport 2025-Q3
2025-08-01 10:00 Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.
2025-06-05 17:54:00

On 24 April 2025, Magle Chemoswed Holding AB ("Magle Group" or the "Company") announced that the Company had signed a share purchase agreement regarding the acquisition of all shares in Saving Chlora AB ("Saving Chlora") (the "Acquisition"). The Acquisition has today, on 5 June 2025, been completed. The purchase price for all shares in Saving Chlora has, in accordance with what previously has been communicated, been paid in the form of seller promissory notes of approximately SEK 4 million, which have been offset against 133,333 newly issued shares in Magle Group, at a subscription price of SEK 30.00 per share. Thus, the Board of Directors of Magle Group has resolved, pursuant to the authorization granted by the Annual General Meeting held on 26 May 2025, on a set-off issue of 133,333 shares in the Company to the sellers of Saving Chlora (the "Set-off Issue").

The subscription price has, in accordance with the share purchase agreement, been set at SEK 30.00 per share. The Board of Directors of Magle Group is of the opinion that the subscription price has been set at market terms through arm's length negotiations and reflects current market conditions and demand.

The Set-off Issue entails that the Company's share capital increases by SEK 6,666.65 through the issuance of 133,333 new shares, corresponding to a dilution of approximately 0.6 percent.

For enquiries, please contact:
Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21

The information was submitted for publication, through the agency of the contact persons set out above, on 5 June 2025 at 17:54 CEST.